



DEFENSE INTELLIGENCE AGENCY

WASHINGTON, D.C. 20340-5100



U-26-4013/IMO-1B (FOIA)

May 31, 2026

Law Office of Mr. Nathaniel M. Lindzen
57 School Street
Wayland, MA 01778

Dear Mr. Lindzen:

This is the 12th interim response to the Freedom of Information Act (FOIA) request dated May 5, 2024 that you submitted to the Defense Intelligence Agency (DIA) requesting records pertaining to 1) correspondence to or from three named individuals containing key terms; 2) genomic analysis authored/performed by the named individuals; 3) a DIA-originated working paper, to include versions and corrections on or before the date of publication. The time frame requested was September 1, 2019 – January 1, 2021.

As you are aware, this case is currently the subject of litigation in the United States District Court for the District of Columbia, case number 24-cv-00982.

A search of DIA's systems of records located documents identified as responsive to the requests described above. This response addresses 102 records (405 pages). Upon review, while considering the foreseeable harm standard, DIA has determined that some portions of 60 documents (241 pages) must be withheld in part from disclosure pursuant to the FOIA. The withheld portions are exempt from release pursuant to Exemptions 1, 3, 5, and 6 of the FOIA, 5 U.S.C. § 552 (b)(1), (b)(3), (b)(5) and (b)(6). Exemption 1 applies to information properly classified under the criteria of Executive Order 13526. Exemption 3 applies to information specifically exempted by a statute establishing particular criteria for withholding. The applicable statutes are 10 U.S.C. § 424 and 50 U.S.C. § 3024(i).¹ Statute 10 U.S.C. § 424 protects the identity of DIA employees, the organizational structure of the agency, and any function of DIA. Statute 50 U.S.C. § 3024(i) protects intelligence sources and methods. Exemption 5 applies to information that falls within one of the civil discovery privileges. In this instance, DIA has asserted the deliberative process privilege. Exemption 6 applies to information which if released would constitute an unwarranted invasion of the personal privacy of other individuals.

¹ The current version of 50 U.S.C. § 3024 took effect on April 23, 2026. Due to modification of the statute, the current 50 U.S.C. § 3024(h) was previously found at 50 U.S.C. § 3024(i). As DIA's processing of the documents for this case occurred both prior to and after the effective date of the modification, any produced documents that have information being withheld via Exemption 3 pursuant to this statute will continue to be marked with 50 U.S.C. § 3024(i) to retain consistency. Any reference to information being withheld pursuant to 50 U.S.C. § 3024(i) should be understood to now be referring to being withheld pursuant to the current 50 U.S.C. § 3024(h).

Further, DIA has determined that 27 documents (80 pages) must be withheld in full from disclosure pursuant to the FOIA. These withheld documents are exempt from release pursuant to Exemptions 1, 3, 6, 7(C), 7(D), and 7(E) of the FOIA, 5 U.S.C. § 552 (b)(1), (b)(3), (b)(6), (b)(7)(C), (b)(7)(D), and (b)(7)(E). Exemption 7(C) applies to personal information in law enforcement records, the disclosure of which could reasonably be expected to constitute an unwarranted invasion of personal privacy. Exemption 7(D) protects law enforcement information, the release of which could disclose a confidential source. Exemption 7(E) protects law enforcement information, the release of which would disclose techniques and procedures for law enforcement investigations or prosecutions, or would disclose guidelines for law enforcement investigations or prosecutions if such disclosure could reasonably be expected to risk circumvention of the law.

Finally, DIA has referred the last 15 documents (84 pages) to other government agencies for review and direct response to you. These referrals were necessary because the documents did not originate with DIA.

DIA has not withheld any reasonably segregable non-exempt portions of the records.

You can expect the next interim response in June 2026.

Sincerely,

A handwritten signature in cursive script, appearing to read "E Wadsworth for".

C. C. Davison
Chief, Records Management and Open Government

From: (b)(3):10 USC 424; (b)(6)
To:
Subject: RE: [redacted]
Date: 2020/06/18 12:35:00
Priority: Normal
Type: Note

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~
~~Declassify On:~~ 20450421

=====

I think names and abstracts are just fine. We have many of the pubs already—surely not all, but we could probably grab additional ones we need pretty easily, or figure out a way to transfer your massive trove.

Thank you,

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)
Sent: Thursday, June 18, 2020 12:33 PM
To: (b)(3):10 USC 424; (b)(6)
Subject: RE: [redacted]

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~
~~Declassify On:~~ 20450421

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, June 18, 2020 8:55 AM

To:

Cc: (b)(3):10 USC 424; (b)(6)

Subject: RE: (b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

(b)(3):10 USC 424; (b)(6)

It looks like tomorrow afternoon may work for both of you. How is 1300? We can do anytime tomorrow.

Thank you!

(b)(3):10 USC 424; (b)(6)

From:

Sent: Wednesday, June 17, 2020 12:32 PM

To:

Cc: (b)(3):10 USC 424; (b)(6)

Subject: RE: (b)(3):10 USC 424; (b)(6)

(b)(1); (b)(3):50 USC 3024(i)
Sec. 1.4(c)

(b)(3):10 USC 424;
(b)(3):50 USC 3024(i);
(b)(6)

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424;
(b)(3):50 USC 3024(i);
(b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

I can do this Friday.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, June 17, 2020 11:53 AM

To:

Cc:

Subject:

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20450421~~

=====

Please do not distribute further

Dear colleagues,

The following page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

Sent Date: 2020/06/18 12:35:45

Delivered Date: 2020/06/18 12:35:00

From: (b)(3):10 USC 424; (b)(6)
To:
Subject:
Date: 2020/06/29 09:36:00
Priority: Normal
Type: Note
(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

~~Classification:~~ TOP SECRET/ (b)(3):50 USC 3024(i)
~~Classified By:~~ (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~ 20451231
=====

(b)(3):10 USC 424; (b)(6)

It's possible I mixed up versions after making some small changes, but I think this is what we reviewed on Friday!

(b)(3):10 USC 424; (b)(6)

=====

~~Classification:~~ TOP SECRET (b)(3):50 USC 3024(i)

Sender: (b)(3):10 USC 424; (b)(6)
Recipient:
Sent Date: 2020/06/29 09:37:09
Delivered Date: 2020/06/29 09:36:00

From: (b)(3):10 USC 424; (b)(6)
To: [Redacted]
Subject: RE: [Redacted]
Date: 2020/05/11 11:59:00
Priority: Normal
Type: Note

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424;

~~Derived From:~~ (b)(6)

~~Declassify On:~~ 20450421

Thanks!

From: (b)(3):10 USC 424; (b)(6)
Sent: Monday, May 11, 2020 11:53 AM
To: [Redacted]
Subject: RE: [Redacted]

(b)(3):10 USC 424;
(b)(6)

(b)(1); (b)(3):50 USC
3024(i); Sec. 1.4(c)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~ [Redacted]

~~Declassify On:~~ 20450421

(b)(3):10 USC
424; (b)(6)

that works for me. Looking forward to the collaboration.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)
Sent: Monday, May 11, 2020 11:36 AM
To: (b)(3):10 USC 424; (b)(6)
Subject: RE: [Redacted]

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~ [Redacted]

~~Declassify On:~~ 20450421

(b)(3):10 USC 424; (b)(6)

The final 3 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: RE: Source help

Date: 2020/11/09 10:25:02

Priority: Normal

Type: Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

On your low side for this reference and information.

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, November 9, 2020 9:51 AM

To:

Subject: Source help (b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

Hi (b)(3):10 USC 424; (b)(6)

Can you please also help find sources for this:

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

CC:

Subject: RE: SARS-CoV-2 origin ACH

Date: 2020/08/10 13:07:00

Priority: Normal

Type: Note

~~Classification: SECRET//NOFORN~~

~~Classified By~~

(b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

Hi

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

Got it, thank you for the update. Wishing a quick and healthy return.

V/r,

(b)(3):10 USC 424; (b)(6)

From

(b)(3):10 USC 424; (b)(6)

Sent: Monday, August 10, 2020 7:08 AM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: SARS-CoV-2 origin ACH

~~Classification: SECRET//NOFORN~~

~~Classified By~~

(b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

Hey

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

So right now we're in a bit of a holding pattern. I'll keep you posted. Also, [redacted] is now out for the next 14 days or so.

VR

[redacted] (b)(3):10 USC 424; (b)(6)

[redacted] (b)(3):10 USC 424; (b)(6)

From: [redacted] (b)(3):10 USC 424; (b)(6)

Sent: Friday, August 07, 2020 3:00 PM

To: [redacted]

Cc: [redacted]

Subject: SARS-CoV-2 origin ACH

[redacted] (b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ [redacted] (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

[redacted] (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Thank you!

V/r,

[redacted] (b)(3):10 USC 424; (b)(6)

=====

~~Classification: SECRET//NOFORN~~

=====

~~Classification: SECRET//NOFORN~~

=====

~~Classification: SECRET//NOFORN~~

Sender:

[redacted] (b)(3):10 USC 424; (b)(6)

Recipient:

Sent Date: 2020/08/10 13:07:56

Delivered Date: 2020/08/10 13:07:00

From: (b)(3):10 USC 424; (b)(6)
To:
CC:

Subject: RE: SARS-COV-2 origin ACH

Date: 2020/07/13 09:13:09

Priority: Normal

Type: Note

~~Classification: TOP SECRET~~

(b)(3):50 USC 3024(i)

~~Classified By:~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

=====

Hi,

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

[redacted] was planning to come into the office this week and we would have a chance to ask [redacted] some questions. I was wondering if there was a date/time for that meeting yet?

Thanks!

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, July 10, 2020 1:51 PM

To:

(b)(3):10 USC 424; (b)(6)

Cc:

Subject: RE: SARS-COV-2 origin ACH

~~Classification: TOP SECRET~~ (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

=====

Hi,

(b)(3):50 USC 3024(i)
On slide 2 of the I can't find it. I would appreciate it if you would please send it to me.

Thanks!

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, July 08, 2020 1:27 PM

To:

Cc:

Subject: RE: SARS-COV-2 origin ACH

(b)(3):10 USC 424;
(b)(6)

~~Classification: TOP SECRET~~ (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

=====

Thanks very much (b)(3):10 USC 424; (b)(6) That's been our experience too, that much of the evidence is (b)(3):50 USC 3024(i)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: [REDACTED]

Sent: Tuesday, July 07, 2020 6:12 PM

To: [REDACTED]

Cc: [REDACTED]

Subject: RE: SARS-COV-2 origin ACH

~~Classification: TOP SECRET~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

We do have a very old ACH from back in February which we will try and dig up for you. What we found unfortunately was that almost all of the evidence was inconclusive.

We appreciate you including us in this process though and are happy to support in any way we can.

The final 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

This is page 3. The first 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

~~Classification:~~ TOP SECRET (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On:~~ 20350705

=====

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From:

Sent: Wednesday, April 22, 2020 3:23 PM

To:

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Cc:

Subject:

~~Classification:~~ TOP SECRET (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50

~~Derived From:~~ USC 3024(i); (b)(6)

~~Declassify On:~~ 20350705

=====

Good afternoon, all,

(TS)

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(b)(3):50 USC 3024(i)

Let us know if we can provide additional information,

(b)(3):10 USC 424; (b)(6)

=====
~~Classification: TOP SECRET/~~
=====
~~Classification: TOP SECRET/~~
=====
~~Classification: TOP SECRET/~~
=====
~~Classification: TOP SECRET/~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

Senders:

Recipient:

Sent Date: 2020/04/23 13:06:50

Delivered Date: 2020/04/23 13:06:00

(b)(3):10 USC 424; (b)(6)

From:

To:

CC:

Subject: RE: (b)(3):50 USC 3024(i)

Date: 2020/04/23 08:12:42

Priority: Normal

Type: Note

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20350705~~

=====

Looks like the [redacted] one is a pre-print. (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, April 23, 2020 8:00 AM

To: [redacted]

(b)(3):10 USC 424; (b)(6)

Cc: [redacted]

Subject: RE: [redacted] (b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20350705~~

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

The following page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

(b)(3):10 USC 424; (b)(6)

(b)(3):50 USC 3024(i)

Subject: [redacted]

~~Classification: TOP SECRET/~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On: 20350705~~

=====

Good afternoon, all,

(TS)

[redacted]

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

Let us know if we can provide additional information,

(b)(3):10 USC 424; (b)(6)

===== (b)(3):10 USC 424; (b)(3):50 USC 3024(i)
~~Classification: TOP SECRET/~~
=====
~~Classification: TOP SECRET/~~
=====
~~Classification: TOP SECRET/~~

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

From: (b)(3):10 USC 424; (b)(6)
To:

Subject: Re: SARS-CoV-2 and HIV

Date: 2020/08/17 10:09:56

Priority: Normal

Type: Note

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From:

Sent: Friday, August 7, 2020 2:57:20 PM

(b)(3):10 USC 424; (b)(6)

To:

Subject: RE: SARS-CoV-2 and HIV

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

(b)(3):10 USC 424; (b)(6)

(b)(3):10
USC 424;
(b)(6)

That all sounds great, and the ACH looks great to me. Thank you for pulling it all together? I'll ping for next steps.

Hope you have a good weekend.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, July 30, 2020 1:03 PM

(b)(3):10 USC 424; (b)(6)

To:

Subject: Re: SARS-CoV-2 and HIV

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, April 28, 2020 8:54 AM

To: (b)(3):10 USC 424; (b)(6)

Subject: SARS-CoV-2 and HIV

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

Thank you for pushing. I agree we should continue to investigate until the trail runs cold.

(b)(3):10 USC 424; (b)(6)

=====

~~Classification: SECRET//NOFORN~~

=====

~~Classification: SECRET//NOFORN~~

Sender: (b)(3):10 USC 424; (b)(6)

Recipient:

Sent Date: 2020/08/17 10:09:50

Delivered Date: 2020/08/17 10:09:56

Subject: FW: FYSA - (b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

-----Original Message-----

From: (b)(3):50 USC 3024(i); (b)(6)

Sent: Wednesday, June 24, 2020 4:00 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: FW: FYSA -

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~ (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~

=====

Hi (b)(3):10 USC 424; (b)(6)

Are you guys tracking this? Do you have any additional info?

Best, (b)(3):50 USC 3024(i); (b)(6)

~~Classification: TOP SECRET~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~

~~Classification: TOP SECRET~~

=====

From: (b)(3):10 USC 424; (b)(6)
To:
Subject: RE: (b)(3):50 USC 3024(i)
Date: 2020/01/31 11:55:00
Priority: Normal
Type: Note

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By: (b)(3):10 USC 424; (b)(6)~~
~~Derived From: Multiple Sources~~
~~Declassify On: 20451231~~
=====

I bet that's a resource many will find useful!

From: (b)(3):10 USC 424; (b)(6)
Sent: Friday, January 31, 2020 11:44 AM
To: (b)(3):10 USC 424; (b)(6)
Subject: RE: (b)(3):50 USC 3024(i)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By: (b)(3):10 USC 424; (b)(6)~~
~~Derived From: Multiple Sources~~
~~Declassify On: 20451231~~
=====

I'm going to add entries from your chart to mine – to make a complete list that includes all the new drugs, as well as the ones that are being looked at for repurposing.

From: (b)(3):10 USC 424; (b)(6)
Sent: Friday, January 31, 2020 11:42 AM
To: (b)(3):10 USC 424; (b)(6)
Subject: RE: (b)(3):50 USC 3024(i)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By: (b)(3):10 USC 424;~~
~~Derived From: Multiple Sources~~
~~Declassify On: 20451231~~
=====

(b)(3):50 USC 3024(i)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 11:38 AM

To:

Subject: RE: (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By: (b)(3):10 USC 424; (b)(6)~~

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 11:33 AM

To:

Subject: RE: (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By: (b)(3):10 USC 424; (b)(6)~~

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

Doesn't it seem to work like that sometimes?! Or maybe you should check your computer security situation...

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 11:31 AM

To:

Subject: RE: (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

~~Classification: CONFIDENTIAL//NOFORN~~

(b)(3):10 USC 424; (b)(6)

~~Classified By:~~

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

Arggggh! I so wish I had seen this two days ago. I put together an almost identical table from hours of hard-searching on the internet! Thank you though!

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 11:30 AM

To:

[Redacted]

Subject: RE:

[Redacted]

(b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424;
(b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424;
(b)(6)

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

[Redacted]

Best,

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 11:11 AM

To:

[Redacted]

The final 6 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

From: (b)(3):10 USC 424; (b)(6)
To:

Subject: RE: SARS-CoV-2 and HIV

Date: 2020/08/03 09:44:00

Priority: Normal

Type: Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~
~~Declassify On: 20450421~~

=====

Hi (b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424

That's great, thank you for sharing the update! I'm just back from leave and catching up. I hope [redacted] is off to a good start. I'll be sending some items related to SARS-CoV-2 origin later today.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)
Sent: Thursday, July 30, 2020 1:03 PM
To:
Subject: Re: SARS-CoV-2 and HIV

(b)(3):10 USC 424; (b)(6)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)
Sent: Tuesday, April 28, 2020 8:54 AM
To:
Subject: SARS-CoV-2 and HIV

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~

~~Declassify On: 20450421~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

Thank you for pushing. I agree we should continue to investigate until the trail runs cold.

(b)(3):10 USC 424; (b)(6)

=====

~~Classification: SECRET//NOFORN~~

=====

~~Classification: SECRET//NOFORN~~

Sender:

(b)(3):10 USC 424; (b)(6)

Recipient:

Sent Date: 2020/08/03 09:44:35

Delivered Date: 2020/08/03 09:44:00

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: RE: 1-pager for DR

Date: 2020/05/01 10:59:00

Priority: Normal

Type: Note

~~Classification: SECRET//NOFORN~~

(b)(3):10 USC 424; (b)(6)

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20450421~~

Thank you!

(b)(3):10 USC 424; (b)(6)

From:

Sent: Friday, May 01, 2020 10:58 AM

To:

Subject: RE: 1-pager for DR

(b)(3):10 USC 424;
(b)(6)

~~Classification: SECRET//NOFORN~~

(b)(3):10 USC 424; (b)(6)

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20450421~~

(b)(3):10 USC
424; (b)(6)

sounds good! I have those papers for you coming on the low-side.

(b)(3):10 USC 424; (b)(6)

From:

(b)(3):10 USC 424; (b)(6)

Sent: Friday, May 1, 2020 9:49 AM

To:

Subject: RE: 1-pager for DR

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

(b)(3):10 USC 424; (b)(6)

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20450421~~

Good idea. How about something like this as a closing paragraph:

The final 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

From: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
To:
Subject: RE: [redacted]
Date: 2020/06/19 08:15:05
Priority: Normal
Type: Note
(b)(1); (b)(3):50 USC 3024(i)
Sec. 1.4(c)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~ 20451231

(b)(3):10 USC 424; (b)(6) ===== (b)(3):10 USC 424; (b)(6)
most appreciate the significant due diligence!!!

From: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
Sent: Thursday, June 18, 2020 1:02 PM
To: (b)(3):10 USC 424; (b)(6)
Subject: [redacted]

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

I think this topic may be a rabbit hole not worth progressing down.

[redacted]
(b)(3):10 USC 424;
(b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: FW: SARS-COV-2 origin ACH

Date: 2020/07/09 12:31:37

Priority: Normal

Type: Note

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(3):50 USC 3024(i)

Sent: Thursday, July 09, 2020 12:27 PM

To:

(b)(3):10 USC 424; (b)(6)

Subject: FW: SARS-COV-2 origin ACH

(b)(3):10 USC 424; (b)(6)

From:

Sent: Thursday, July 09, 2020 12:15 PM

To:

(b)(3):50 USC 3024(i); (b)(6)

Subject: FW: SARS-COV-2 origin ACH

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~

~~Classified By:~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, July 08, 2020 1:26 PM

To: (b)(3):10 USC 424; (b)(6)

Cc: (b)(3):10 USC 424; (b)(6)

Subject: RE: SARS-COV-2 origin ACH

~~Classification:~~ TOP SECRET/ (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On:~~ 20451231

=====

Thanks very much (b)(3):10 USC 424; (b)(6) That's been our experience too, that much of the evidence is (b)(3):50 USC 3024(i)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, July 07, 2020 6:12 PM

To: (b)(3):10 USC 424; (b)(6)

Cc:

Subject: RE: SARS-COV-2 origin ACH

(b)(3):10 USC 424;
(b)(6)

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20151231~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

(b)(3):10 USC 424; (b)(6)

We do have a very old ACH from back in February which we will try and dig up for you. What we found unfortunately was that almost all of the evidence was inconclusive.

We appreciate you including us in this process though and are happy to support in any way we can.

Thanks,

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

Sent: Tuesday, July 7, 2020 2:01 PM

To:

(b)(3):10 USC 424; (b)(6)

Cc:

Subject: SARS-COV-2 origin ACH

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET~~

~~Classified By:~~

~~Derived From:~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

The final 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

From: (b)(3):10 USC 424; (b)(6)

To:

Subject: (U) RE: [REDACTED]

Date: 2020/11/03 16:49:30

Priority: Normal

Type: Note

(b)(1); (b)(3):50 USC
3024(i); Sec. 1.4(c)

~~Classification: TOP SECRET/~~

(b)(3):10 USC 424; (b)(3):50 USC
3024(i)

~~Classified By:~~

(b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)

Would you please forward this document as well?

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

Thanks.

(b)(3):50 USC 3024(i); (b)(6)

From:

(b)(3):10 USC 424; (b)(6)

Sent: Monday, November 2, 2020 11:01 AM

To: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Subject: FW: [REDACTED]

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

~~Classification: TOP SECRET/~~

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20451231~~

(b)(3):10 USC 424;
(b)(3):50 USC 3024(i);
(b)(6)

(b)(3):10 USC 424; (b)(3):50
USC 3024(i)

=====

Sir, for your SA.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, October 30, 2020 2:14 PM

To:

(b)(3):10 USC 424; (b)(6)

The remaining 3 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

From: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
To:
Subject: (b)(3):10 USC 424; (b)(3):50 USC 3024(i)
Date: 2020/06/10 15:55:12
Priority: Normal
Type: Note

(b)(3):10 USC 424; (b)(6)

Please find attached an updated version....

(b)(3):10 USC 424; (b)(6)

Sender: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
Recipient:
Sent Date: 2020/06/10 15:55:11
Delivered Date: 2020/06/10 15:55:12

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: FW: Status of draft

Date: 2020/11/18 06:34:31

Priority: Normal

Type: Note.SMIME.MultipartSigned

~~Classification: TOP SECRET//~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);

~~Derived From:~~ (b)(6)

~~Declassify On:~~

=====

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, November 17, 2020 10:04 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: Status of draft

~~Classification: TOP SECRET//~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);

~~Derived From:~~ (b)(6)

~~Declassify On:~~

=====

All,

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

I will be out of the office tomorrow, so please direct any outstanding questions to

(b)(3):10 USC 424; (b)(6)

Thanks,

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, November 17, 2020 7:56 PM

To:

Cc: (b)(3):10 USC 424; (b)(6)

Subject: RE: Status of draft

~~Classification: TOP SECRET/~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);

~~Derived From:~~ (b)(6)

~~Declassify On:~~

Team,

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

First, really strong work as you have given time and again. You are appreciated.

The following page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

(b)(3):10 USC 424

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, November 17, 2020 5:44 PM

To:

Cc:

Subject: RE: Status of draft

(b)(3):10 USC 424; (b)(6)

~~Classification: TOP SECRET//~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);

~~Derived From:~~ (b)(6)

~~Declassify On:~~

=====

Slightly updated, clean and tracked changes versions attached.

(b)(3):10 USC 424; (b)(6)

please review remaining comments on the tracked changes version.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, November 17, 2020 12:00 PM

To:

Cc:

Subject: FW: Status of draft

(b)(3):10 USC 424; (b)(6)

~~Classification: TOP SECRET~~

(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);
~~Derived From:~~ (b)(6)
~~Declassify On:~~

=====

(b)(3):10 USC 424; (b)(6)

Attached is the updated draft based on our conversation last night. I included a clean version and a version with tracked changes/comments. [redacted] is not working so there is one [redacted] I can't [redacted] unfortunately.

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, November 16, 2020 4:44 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: RE: Status of draft

~~Classification: TOP SECRET~~

(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);
~~Derived From:~~ (b)(6)
~~Declassify On:~~

=====

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, November 16, 2020 2:36 PM

To: (b)(3):10 USC 424; (b)(6)

Cc:
Subject: FW: Status of draft

~~Classification: TOP SECRET~~
(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i);
~~Derived From:~~ (b)(6)
~~Declassify On:~~

=====

Apologies, forgot to cc you

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, November 16, 2020 1:31 PM

To:
Cc: (b)(3):10 USC 424; (b)(6)

Subject: FW: Status of draft

~~Classification: TOP SECRET~~
(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~

=====

Hello,

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From

(b)(3):50 USC 3024(i); (b)(6)

Sent: Monday, November 16, 2020 9:27 AM

To

Cc

Subject: Status of draft

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By~~

(b)(3):50 USC 3024(i); (b)(6)

~~Derived From~~

~~Declassify On: 20451231~~

Morning

(b)(3):10 USC 424

Can you give us an update on the

(b)(3):50 USC 3024(i)

(b)(3):50 USC 3024(i); (b)(6)

In the event I am out of the office, please contact the following alternate POCs

(b)(3):50 USC 3024(i)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

From:	(b)(3):10 USC 424; (b)(6)
To:	
Subject:	Background Genetics info
Date:	2020/03/19 14:49:55
Priority:	Normal
Type:	Note

~~Classification:~~ UNCLASSIFIED//~~FOUO~~

=====

Hi,

FYSA, this is a good primer for the differences in SARS-CoV-2 vs SARS.

(b)(3):10 USC 424; (b)(6)

=====

~~Classification:~~ UNCLASSIFIED//~~FOUO~~

Sender:	(b)(3):10 USC 424; (b)(6)
Recipient:	
Sent Date:	2020/03/19 14:49:54
Delivered Date:	2020/03/19 14:49:55

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: FW: [REDACTED]

Date: 2020/09/10 08:27:36

Priority: Normal

Type: Note

(b)(1); (b)(3):50 USC 3024(i);
Sec. 1.4(c); Sec. 1.4(e)

~~Classification: TOP SECRET//~~

(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424;
(b)(6)

~~Derived From: Multiple Sources~~

(b)(3):50 USC 3024(i)

~~Declassify On~~

(b)(3):10 USC 424; (b)(6)

From: (b)(3):50 USC 3024(i); (b)(6)

Sent: Wednesday, September 09, 2020 5:39 PM

To: [REDACTED]

Subject: [REDACTED]

(b)(3):10
USC 424;
(b)(6)

(b)(3):10 USC 424; (b)(6)

(b)(1); (b)(3):50 USC 3024(i);
Sec. 1.4(c); Sec. 1.4(e)

Please find attached the executive summary...

R/

From:

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Sent: Friday, September 4, 2020 1:16 PM

To: [REDACTED]

Cc: [REDACTED]

The final 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

(b)(3):10
USC 424;
(b)(3):50
USC
3024(i);
(b)(6)

(b)(3):50 USC 3024(i); (b)(6)

Subject: RE: (U//FOUO)

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET/~~

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

(b)(3):50 USC 3024(i); (b)(6)

Thank you so much for getting back to us on this, [redacted] We appreciate the quick turn! You already probably know this, but we will be eager to see any future information you might receive on this topic! Thank you again!!

(b)(3):10 USC 424; (b)(6)

(b)(3):50 USC 3024(i);
(b)(6)

From: [redacted]

Sent: Wednesday, April 22, 2020 12:49 PM

To: [redacted]

Cc: [redacted]

(b)(3):10
USC 424;
(b)(3):50
USC
3024(i);
(b)(6)

Subject: RE: (U//FOUO)

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET/~~

(b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

Following up on our phone discussion, here is my attempt to answer your questions. I hope this helps, and let me know if I missed any out any of your questions.

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c)

(b)(3):10 USC 424; (b)(6)

From:

To:

CC:

Subject: FW: [From NIPRNet] citation

Date: 2020/11/16 09:00:05

Priority: Normal

Type: Note

~~Classification: SECRET//NOFORN~~

(b)(3):10 USC 424; (b)(6)

~~Classified By:~~

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====
(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

-----Original Message-----

From:

(b)(3):10 USC 424; (b)(6)

Sent: Friday, November 13, 2020 10:49 AM

To:

Cc:

(b)(3):10 USC 424;
(b)(6)

Subject: FW: [From NIPRNet] citation

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

Hi

(b)(3):50 USC
3024(i)

and I couldn't find your reference
back in during coord.

so we deleted it. If you think it is imperative that it be added we can add it

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC
424; (b)(6)

-----Original Message-----

From: [REDACTED]
Sent: Friday, November 13, 2020 10:47 AM
To: [REDACTED]
Subject: RE: [From NIPRNet] citation

(b)(3):10 USC 424;
(b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Derived From: Multiple Sources~~
~~Declassify On: 20451231~~

(b)(3):10 USC 424; (b)(6)

I am going to delete it as we already have numerous sources.

(b)(3):10 USC 424; (b)(6)

-----Original Message-----

From: [REDACTED]
Sent: Friday, November 13, 2020 10:34 AM
To: [REDACTED]
Subject: RE: [From NIPRNet] citation

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Derived From: Multiple Sources~~
~~Declassify On: 20451231~~

(b)(3):10 USC 424; (b)(6)

I can't find a [REDACTED] that is related to this work. Wonder if it's a misspelling?

(b)(3):10 USC 424; (b)(6)

-----Original Message-----

From: [REDACTED]
Sent: Friday, November 13, 2020 10:31 AM
To: [REDACTED]
Subject: RE: [From NIPRNet] citation

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

Pages 3-6 are withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and are not provided.

From: (b)(3):10 USC 424; (b)(6)
To:
Subject: FW: (b)(3):50 USC 3024(i)
Date: 2020/11/17 10:52:53
Priority: Normal
Type: Note

~~Classification:~~ TOP SECRET/ (b)(3):50 USC 3024(i)
~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~ Multiple Sources
~~Declassify On:~~ (b)(3):50 USC 3024(i)
=====

Is this what you are thinking of?

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)
Sent: Monday, November 09, 2020 7:43 AM
To: (b)(3):10 USC 424; (b)(6)
Subject: FW: (b)(3):50 USC 3024(i)

~~Classification:~~ TOP SECRET/ (b)(3):50 USC 3024(i)
~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~ Multiple Sources
~~Declassify On:~~ (b)(3):50 USC 3024(i)
=====

We can discuss this for a very brief insert into paper.

From:
Sent: Monday, November 9, 2020 6:47 AM
To: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
Subject:

~~Classification: TOP SECRET~~

~~Classified By~~

~~Derived From: Multiple Sources~~

~~Declassify On:~~

=====

Just gonna copy and paste some sentences:

and vectored in a yeast-based synthetic genomic platform. Using this technology, SARS-CoV-2 was reconstructed within a week (Thao et al. 2020). However, despite this successful recreation of SARS-CoV-2, these large viruses have been difficult to reverse engineer (Almazán et al. 2014)

SARS-CoV identified in civets had 99.8% homology to SARS-CoV-1 (Guan et al., 2003). MERS-CoV in humans is similar to the virus in camels (Chu et al. 2014).

(b)(1); (b)(3);50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

identified SARS-like bat CoV, WIV1, considered a progenitor to SARS-CoV-1

The first

In July 2013,

WIV16, was isolated from *Rhinolophus sinicus* bats in the Yunnan province. WIV16 has a 95% nucleotide and 97% amino acid identity to SARS-CoV-1 (Yang et al. 2016). WIV16, with a 97% amino acid similarity, can use bat, civet, and human ACE2 receptors for cell entry (Ge et al. 2013).

(b)(3);10 USC 424; (b)(6)

[REDACTED]

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From: [REDACTED]

Sent: Monday, November 9, 2020 6:08 AM

To: [REDACTED]

Subject: [REDACTED]

~~Classification: TOP SECRET~~

~~Classified By:~~ [REDACTED]

~~Derived From: Multiple Sources~~

~~Declassify:~~ [REDACTED]

=====

[REDACTED] need your assistance on this. Will call shortly.

From: [REDACTED]

Sent: Friday, November 6, 2020 9:37 PM

To: [REDACTED]

Subject: [REDACTED]

~~Classification: TOP SECRET~~

~~Classified By:~~ [REDACTED]

~~Derived From: Multiple Sources~~

~~Declassify On:~~ [REDACTED]

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

[REDACTED]

	(b)(3):10 USC 424; (b)(6)
From:	
To:	
CC:	
Subject:	FW: Be careful what you ask for ;>)
Date:	2020/11/16 12:54:08
Priority:	Normal
Type:	Note

~~CLASSIFICATION: TOP SECRET~~
(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~ Multiple Sources
~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

(b)(3):10 USC 424; (b)(6)
Hi

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

it is tradecraft compliant however. Would staying beyond 1600 be allowed? I will send the corrected [redacted] back to everyone shortly.

Thank you,

(b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

Sent: Friday, November 13, 2020 4:35 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: Be careful what you ask for ;>)

~~Classified By: [redacted]~~

(b)(3):50 USC 3024(i)

~~Classified By:~~

~~Derived From: Multiple Sources~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

Hi:

(b)(3):10 USC 424; (b)(6)

said that since you had an extension till Wednesday, If I had any further comments, to fire away.

Attached is a quick cut of your paper that if bathed and given a party dress may tell your story a bit better. It is almost entirely lacking in proper assessments and tradecraft – apologies but I was working quickly.

(b)(3):50 USC 3024(i)

The final 2 pages are withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and are not provided.

From:	(b)(3):10 USC 424; (b)(6)
To:	
Subject:	FW: Paper for (b)(3):10 USC 424
Date:	2020/05/15 13:12:34
Priority:	Normal
Type:	Note

~~Classification:~~ UNCLASSIFIED//~~FOUO~~

FYSA, I'll let you know what they say (See below)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, May 15, 2020 1:11 PM

To: (b)(3):50 USC 3024(i); (b)(6)

Subject: Paper for (b)(3):10 USC 424

~~Classification:~~ UNCLASSIFIED//~~FOUO~~

Hello,

Thank for putting on the (b)(3):10 USC 424 call today. As always, it was very interesting and useful.

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

The final page is withheld in full citing (b)(3) 10 USC 424 and (b)(6) and is not provided.

	(b)(3):10 USC 424; (b)(6)	
From:		
To:		
CC:		
Subject: FW: (b)(3):50 USC 3024(i)		
Date: 2020/02/24 14:01:00		
Priority: Normal		
Type: Note		

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

facilities of interest are in the Word document.

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC
424; (b)(6)

From: [redacted]
Sent: Wednesday, February 19, 2020 9:31 AM
To: [redacted]
Cc: [redacted]

Subject: FW: [redacted] (b)(3):50 USC 3024(i)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By:~~ [redacted] (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(1); (b)(3):10 USC 424; Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):50 USC 3024(i); (b)(6)

Sent: Wednesday, February 19, 2020 9:09 AM

To:

Subject: RE: (b)(3):50 USC 3024(i)

(b)(3):10 USC 424;
(b)(6)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By:~~ (b)(3):50 USC 3024(i); (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

(b)(3):50 USC
3024(i)

Thank you. I very much appreciate this. I presume you are tracking the open source reporting

From:

Sent: Tuesday, February 18, 2020 11:45 AM

To:

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Cc:

Subject: (b)(3):50 USC 3024(i)

~~Classification: CONFIDENTIAL//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

Hello,

(b)(3):50 USC 3024(i); (b)(6)

gave an update to the nCoV situation on 2/13 and answered some questions from the IC. I am sending out my notes as they might be helpful for multiple people.

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

The final 4 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

(b)(3):10
USC 424;
(b)(6)

	(b)(3):10 USC 424; (b)(6)
From:	
To:	
Subject:	Genetic engineering
Date:	2020/11/06 08:55:59
Priority:	Normal
Type:	Note

~~Classification:~~ UNCLASSIFIED//~~FOUO~~
=====

[Redacted]

a draft bullet as follows: I will want to modify this with you early next week so we can put our best thoughts forward.

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

=====
~~Classification:~~ UNCLASSIFIED//~~FOUO~~

Sender:	(b)(3):10 USC 424; (b)(6)
Recipient:	

Sent Date:	2020/11/06 08:55:58
Delivered Date:	2020/11/06 08:55:59

Sent Date:	2020/05/14 13:59:59
Delivered Date:	2020/05/14 14:00:02

	(b)(3):10 USC 424; (b)(6)
From:	
To:	
CC:	
Subject: RE:	
Date: 2020/03/25 17:39:00	
Priority: Normal	(b)(3):50 USC 3024(i)
Type: Note	

~~Classification: SECRET / (NOFORN)~~

~~Classified By: (b)(3):10 USC 424; (b)(6)~~
~~Derived From: Multiple Sources~~
~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)
These look like great ideas to me! I will check with you tomorrow to see if I can plug in anywhere;
happy to help as needed.

Thank you,

(b)(3):10 USC 424; (b)(6)

From:	
Sent: Wednesday, March 25, 2020 2:16 PM	
To:	
Cc:	(b)(3):10 USC 424; (b)(6)
Subject: RE:	(b)(3):50 USC 3024(i)

The remaining 5 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

	(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
From:	
To:	
CC:	
Subject:	RE: (U) Coronavirus Coauthors
Date:	2020/06/25 15:33:22
Priority:	Normal
Type:	Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~

=====

Agreed! Thanks for closing the loop ☺

From:	
Sent:	Thursday, June 25, 2020 3:28 PM
To:	
	(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
Cc:	

Subject: RE: (U) Coronavirus Coauthors

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

[redacted] - I do like it want the IC comes full circle and you see your product come right back to you.
[redacted] Like the fact that the system works!

Thanks for forwarding [redacted] Cheers

[redacted]
(b)(3):10 USC 424; (b)(6)

From: [redacted]

Sent: Thursday, June 25, 2020 11:24 AM

To: [redacted]

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Cc: [redacted]

Subject: RE: (U) Coronavirus Coauthors

~~Classification:~~ SECRET//NOFORN

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~ [redacted]

~~Declassify On:~~

Thanks [redacted]

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

[redacted]
Please let me know if there are any questions.

Thanks,

(b)(3):10 USC 424; (b)(6)

From:

Sent: Thursday, June 25, 2020 11:07 AM

To:

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Cc:

Subject: RE: (U) Coronavirus Coauthors

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On:~~

thanks for this

any of this ping in your trackers?

(b)(3):10 USC 424; (b)(3):50
USC 3024(i); (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

(b)(3):50 USC 3024(i); (b)(6)

Sent: Friday, June 19, 2020 12:20 PM

To:

(b)(3):10 USC 424; (b)(6)

Subject: (U) Coronavirus Coauthors

~~Classification: SECRET//NOFORN~~

~~Message Body Classification: SECRET//NOFORN~~

(b)(3):50 USC 3024(i)

ALCON,

(b)(3):10 USC 424; (b)(6)

(U//~~CU~~) Some nice data aggregation from [redacted] asked me to share this with you.

(b)(3):50 USC 3024(i); (b)(6)

The following page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: [REDACTED]

Sent: Tuesday, June 9, 2020 9:11 AM

To: [REDACTED]

Cc: [REDACTED]

(b)(3):10 USC 424; (b)(6)

Subject: RE: Review of Andersen paper

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ [REDACTED]

~~Derived From:~~ [REDACTED]

~~Declassify On: 20450421~~

=====

[REDACTED] (b)(3):10 USC 424; (b)(6)

Thanks so much, [REDACTED] We appreciate how busy you all are, and are happy to be fit into your schedule however is best for you. This is an ongoing analysis, and we do not have a specific date after which this would not be useful.

Best,

From [REDACTED]

Sent: Monday, June 08, 2020 3:20 PM

To: [REDACTED]

(b)(3):10 USC 424; (b)(6)

Cc: [REDACTED]

Subject: RE: Review of Andersen paper

~~Classification: SECRET//NOFORN~~

We will pull together the author affiliations and work out how best to display networks. Can you let us know your timeline for this effort?

Thanks,

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From

Sent: Monday, June 8, 2020 3:05 PM

To:

Cc:

Subject: RE: Review of Andersen paper

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Declassify On:~~

~~Declassify On:~~ 20450421

(b)(3):10 USC 424; (b)(6)

Thank you for considering! Sounds like you've assembled a great resource for these queries.

The following 3 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

~~Declassify on: 20150121~~

=====

(b)(1); (b)(3); 10 USC 424; (b)(3); 50 USC
3024(i); Sec. 1.4(c); Sec. 1.4(e)

Sent: Wednesday, June 3, 2020 1:38 PM

To:

Cc:

Subject: RE: Review of Andersen paper

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Reviewed From:~~

~~Declassify on: 20150121~~

Thank you for the excellent comments! We strive for full nerd at all times, so this is most welcome. We will incorporate them into the next version.

The following 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

=====
Attachment Classification: SECRET//NOFORN

=====
Message Body Classification: SECRET//NOFORN

=====
Classification: SECRET//NOFORN

	(b)(3):10 USC 424; (b)(6)
From:	
To:	
CC:	
Subject: RE:	
Date: 2020/03/26 09:54:19	(b)(3):50 USC 3024(i)
Priority: Normal	
Type: Note	

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Sorry – that was a lot of stream of consciousness, but wanted to have it all down in one place.

The remaining 5 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From:

To:

Subject: RE: Bio Attribution Framework

Date: 2020/08/06 18:15:29

Priority: Normal

Type: Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)

Hi [REDACTED]

I completely concur with [REDACTED] below. Happy to help in any way, and loop in any others you may need POCs for, so count me in. I have to admit, the original email list was a who's who of my career – so many good people☺.

Chat soon,

[REDACTED] (b)(3):10 USC 424; (b)(6)

From: (b)(3):50 USC 3024(i); (b)(6)

Sent: Thursday, August 06, 2020 1:31 PM

To: [REDACTED]

Cc: [REDACTED] (b)(3):10 USC 424; (b)(6)

Subject: RE: Bio Attribution Framework

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)

Thanks, [REDACTED] I'll reach out to the folks recommended below. I am open to having conversations at the FOUO level, but any SOP/Annexes that accompany the policy will surely be classified.

(b)(3):10 USC 424; (b)(6)

From: [REDACTED]

Sent: Thursday, August 6, 2020 9:42 AM

To: [REDACTED]

(b)(3):50 USC 3024(i); (b)(6)

The next page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

[REDACTED]

Subject: Bio Attribution Framework

~~Classification:~~ SECRET//NOFORN

~~Classified By:~~ [REDACTED]

~~Derived From:~~ [REDACTED]

~~Declassify On:~~ 20451231

=====

(b)(3):10 USC 424: (b)(3):50 USC 3024(i): (b)(6)

Dear Colleagues,

I am in the early stages of planning for a sub-PCC/working group level meeting on a Bio Attribution Framework.

[REDACTED]

The first sub-PCC discussion would seek to:

[REDACTED]

(b)(1): Sec. 1.4(c): (b)(5)

Can you please help identify POC(s) from your departments and agencies for this issue, as well as flag any omissions in my initial outreach? It is my intent that through this message I cast a wide net to ensure maximum participation and identification of existing guidance, policy, SOPs, etc.

I appreciate that many folks are on a Team A/B schedule, so kindly request your feedback NLT Wednesday, August 19.

Thank you for your support,

[REDACTED]

(b)(3):50 USC
3024(i): (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)	
From:	
To:	
Subject: RE: Can we meet for 5 mins in my office, please, @1330	
Date: 2020/02/12 13:55:18	
Priority: Normal	
Type: Note	

~~CLASSIFICATION:~~ UNCLASSIFIED

Note to Briefer:

DIA [redacted] has adopted the official World Health Organization (WHO) and Centers for Disease Control and Prevention's (CDC) nomenclature for the 2019 novel coronavirus. When describing the disease associated with the novel coronavirus, DIA [redacted] will use the term COVID-19. DIA [redacted] will use the term SARS-CoV-2 when describing the virus characteristics or the virus itself.

Please feel free to let me know if this needs additional clarifications. Happy to continue to expand, but wanted to make it short and to the point to start with initially.

(b)(3):10 USC 424; (b)(6)		(b)(3):10 USC 424; (b)(6)
From:		
Sent: Wednesday, February 12, 2020 1:20 PM		
To:		
Subject: Can we meet for 5 mins in my office, please, @1330		
Importance: High		

~~CLASSIFICATION:~~ UNCLASSIFIED

The final page is withheld in full citing (b)(3) 10 USC 424 and (b)(6) and is not provided.

From: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
To:
Subject: RE: Corona Virus draft
Date: 2020/03/04 14:01:36
Priority: Normal
Type: Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~ 20451231
=====

Thanks [redacted] I'm in after 3pm and in the morning from 0830

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)
Sent: Wednesday, March 4, 2020 7:08 AM
To: (b)(3):50 USC 3024(i); (b)(6)
Subject: RE: Corona Virus draft

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~ 20451231
=====

Sir, will call this morning to discuss.

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):50 USC 3024(i); (b)(6)

Sent: Monday, March 2, 2020 3:51 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: RE: Corona Virus draft

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)

Any movement on the proposal?

(b)(3):50 USC 3024(i); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, February 25, 2020 12:11 PM

To:

Subject: Corona Virus draft

(b)(3):50 USC 3024(i);
(b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On: 20451231~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

	(b)(3):10 USC 424; (b)(6)
From:	
To:	
CC:	
Subject:	RE: Coronavirus research capabilities (b)(3):10 USC 424; (b)(6)
Date:	2020/06/02 13:54:18
Priority:	Normal
Type:	Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

(b)(3):50 USC 3024(i)

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

Sent: Tuesday, June 02, 2020 9:50 AM

To: (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

Cc:

Subject: Coronavirus research capabilities

~~Classification: SECRET//NOFORN~~

~~Classification:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify on: EOTB~~

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

I'm usually in the office until at least 1500, and can usually stay later than that, if we should talk through it.

Thank you!

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classification: SECRET//NOFORN~~

Sender:

Recipient:

(b)(3):10 USC 424; (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 and (b)(6) and is not provided.

From: (b)(3):10 USC 424; (b)(6)
To:
Subject: RE: hope this helps
Date: 2020/12/02 11:07:28
Priority: Normal
Type: Note

~~Classification: SECRET/~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Classified By:~~
~~Derived From:~~
~~Declassify on: 20350705~~
=====

Haven't seen this exact one so thank you! He seems legit. He is developing a COVID vaccine or therapeutic, whatever. Lots of pubs (b)(3):50 USC 3024(i); (b)(6)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From:
Sent: Wednesday, December 2, 2020 10:42 AM
To:
Subject: RE: hope this helps

~~Classification: SECRET/~~
~~Classified By:~~
~~Derived From:~~

~~Declassify On: 20250705~~

=====

[redacted] have you seen the attached? V/R [redacted]

From [redacted]

Sent: Wednesday, December 2, 2020 7:58 AM

To: [redacted]

Subject: hope this helps

~~Classification: SECRET~~

~~Classified By~~

~~Derived From~~

~~Declassify On: 20250705~~

(b)(3); 10 USC 424; (b)(1);
(b)(3); 50 USC 3024(i); Sec.
1.4(c); Sec. 1.4(e); (b)(6)

The final 2 pages are withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and are not provided.

	(b)(3):10 USC 424
From:	
To:	
CC:	
Subject:	RE: Coronavirus research capabilities
Date:	2020/06/04 14:23:00
Priority:	Normal
Type:	Note

(b)(3):50 USC 3024(i)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Declassify On:~~

~~Declassify On: 20450421~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From:		
Sent:	Wednesday, June 03, 2020 10:38 PM	(b)(3):10 USC 424; (b)(6)
To:		
Cc:		
Subject:	RE: Coronavirus research capabilities	(b)(3):50 USC 3024(i)

~~Classification: SECRET//NOFORN~~

(b)(3):10 USC
424: (b)(6)

~~Classified By:~~ [redacted]

~~Derived From:~~ [redacted]

~~Declassify On: 20450421~~

=====

[redacted]

(b)(3):50 USC 3024(i)

From: [redacted]

Sent: Tuesday, June 02, 2020 9:50 AM

To: [redacted]

Cc: [redacted]

Subject: Coronavirus research capabilities [redacted]

(b)(3):10 USC 424: (b)(3):50
USC 3024(i): (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~ [redacted]

~~Declassify On: 20450421~~

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

I'm usually in the office until at least 1500, and can usually stay later than that, if we should talk through it.

The final page is withheld in full citing (b)(3) 10 USC 424 and (b)(6) and is not provided.

From:	(b)(3):10 USC 424; (b)(6)
To:	
CC:	
Subject:	RE: (b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)
Date:	2020/01/31 12:55:39
Priority:	Normal
Type:	Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10
USC 424

If you want to use the big round table in feel free. We're looking into it too.

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 12:54 PM

To:

(b)(3):10 USC 424; (b)(6)

Cc:

Subject: RE

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i);
Sec. 1.4(c); Sec. 1.4(e); (b)(6)

Yes...That's why I sent this out...Be right over.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 12:53 PM

To:

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

Cc:

Subject: RE [REDACTED]

~~Classification: SECRET//NOFORN~~

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

~~Classified By: (b)(3):10 USC 424; (b)(6)~~

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

=====

[REDACTED]
Perhaps we should chat?

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, January 31, 2020 12:48 PM

To:

[REDACTED]
(b)(3):10 USC 424; (b)(6)

Subject: [REDACTED]

~~Classification: SECRET//NOFORN~~

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

~~Classified By: (b)(3):10 USC 424; (b)(6)~~

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)

Thanks for this!

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

ALCON,

We're trying to get a first draft together by COB today. Inputs are much appreciated.

Pages 4-10 are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

(b)(3):10 USC 424; (b)(6)

From: [REDACTED]

To: [REDACTED]

Subject: RE: Need source

Date: 2020/11/12 10:55:12

Priority: Normal

Type: Note

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET/~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, November 12, 2020 10:53 AM

To: (b)(3):10 USC 424; (b)(6)

Subject: RE: Need source

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET/~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

Yes, and [REDACTED] agrees. Thanks/ (b)(3):10 USC 424; (b)(6)

From: [REDACTED]

Sent: Thursday, November 12, 2020 10:48 AM (b)(3):10 USC 424; (b)(6)

To: [REDACTED]

Subject: Need source

Importance: High

(b)(3):50 USC 3024(i)

~~Classification: TOP SECRET/~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

The final page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

From: (b)(3):10 USC 424; (b)(6)
To: [Redacted]
Subject: Re: New lead with (b)(3):50 USC 3024(i)
Date: 2020/10/05 07:53:11
Priority: Normal
Type: Note

(b)(3):10 USC 424;
(b)(6)

yes I am very interested in the source and information on the topics that they wish to share.

From: [Redacted]
Sent: Friday, October 2, 2020 10:22:25 AM
To: [Redacted]
Subject: New lead with (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
~~Derived From:~~
~~Declassify On:~~

Good Morning,

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

(b)(3):10 USC 424; (b)(6)

From: [redacted]

To: [redacted]

Subject: Re: (b)(3):50 USC 3024(i)

Date: 2020/10/08 09:48:10

Priority: Normal

Type: Note

[redacted] I have not seen this. Thanks for sharing! [redacted] (b)(3):10 USC 424; (b)(6)

From: [redacted]

Sent: Thursday, October 8, 2020 9:26:16 AM

To: [redacted]

Subject: [redacted] (b)(3):50 USC 3024(i)

(b)(3):10
USC 424;
(b)(6)

~~Classification: SECRET//NOFORN~~
~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~
~~Declassify On: 20360916~~

FROM THE [redacted] - below - Have you seen this? I have yet to see this for review.
(b)(3):10 USC 424; (b)(6)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

~~Classification: SECRET//NOFORN~~

Sender: (b)(3):10 USC 424; (b)(6)

Recipient: [redacted]

Sent Date:	2020/10/08 09:48:09
Delivered Date:	2020/10/08 09:48:10

	(b)(3):10 USC 424; (b)(6)
From:	
To:	
CC:	
Subject: RE:	
Date: 2020/11/13 11:12:31	(b)(3):50 USC 3024(i)
Priority: Normal	
Type: Note	

~~Classification: TOP SECRET~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~ MULTIPLE SOURCES
~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

All,

Thank you for your work on this. I have started my comments (in pen, sorry) and will have them to the team on Monday at about 3 pm transcribed into the digits. Before that gets to you, I'd like you to relook

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

Thanks for your hard work on this!

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, November 12, 2020 10:21 PM

To:

Cc:

Subject:

~~Classification: TOP SECRET~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

Lastly, thank you everyone for all your help pulling this together on such short suspense. We really appreciate everyone's willingness to contribute and get this done!

(b)(3):10 USC 424; (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

This is page 3. The first 2 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided. In addition, the final 2 pages are likewise withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and are not provided.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, November 9, 2020 6:08 AM

To: (b)(3):10 USC 424; (b)(6)

Subject: FW: (b)(3):50 USC 3024(i)

~~Classification:~~ TOP SECRET/ (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~ Multiple Sources

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

(b)(3):10 USC 424;
(b)(6)

need your assistance on this. Will call shortly.

(b)(3):10 USC 424;
(b)(6)

From: (b)(3):10 USC 424

Sent: Friday, November 6, 2020 9:37 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: RE: (b)(3):50 USC 3024(i)

~~Classification:~~ TOP SECRET/ (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From:~~ Multiple Sources

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

This is page 2. The first page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided. Similarly, the final 2 pages are withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6), and are not provided.

~~Declassify On: 20451231~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, October 07, 2020 2:05 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: Question about Sequence Read Archive

~~Classification: UNCLASSIFIED//FOUO~~

=====

Hi,

I ran across the attached article in Genetic Engineering and Biotechnology News which quotes a Stanford University researcher about why she doesn't think the virus came from a lab (see below). I'd appreciate your insights as to the accuracy of the highlighted section.

Thanks,

(b)(3):10 USC 424; (b)(6)

"Massa Shoura, PhD, a pathology researcher at Stanford University, was part of a team that performed a comprehensive search of the Sequence Read Archive (SRA), a public database used by researchers to deposit newly identified DNA and RNA sequences.

This is page 2. The first page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, October 8, 2020 8:34 AM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: Question about Sequence Read Archive

~~Classification:~~ SECRET//

(b)(3):10 USC 424

~~Classified By:~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On:~~ 20451231

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, October 07, 2020 2:05 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: Question about Sequence Read Archive

~~Classification:~~ UNCLASSIFIED//~~FOUO~~

=====

Hi,

I ran across the attached article in Genetic Engineering and Biotechnology News which quotes a Stanford University researcher about why she doesn't think the virus came from a lab (see below). I'd appreciate your insights as to the accuracy of the highlighted section.

Thanks,

(b)(3):10 USC 424; (b)(6)

"Massa Shoura, PhD, a pathology researcher at Stanford University, was part of a team that performed a comprehensive search of the Sequence Read Archive (SRA), a public database used by researchers to deposit newly identified DNA and RNA sequences.

(b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(6)

=====
~~Classification:~~ UNCLASSIFIED//~~FOUO~~

The final page is withheld in full citing (b)(3) 10 USC 424 and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

CC:

Subject: RE: Quick Turn

Date: 2020/02/24 07:50:18

Priority: Normal

Type: Note

(b)(3):50 USC 3024(i)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

~~Derived From:~~

~~Declassify On:~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, February 24, 2020 7:30 AM

To:

Cc:

Subject: RE: Quick Turn

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On:~~

Good morning all,

I few questions to add:

- What is the laboratory testing capacity? How many tests can they run daily
- Are they prioritizing who receives lab testing, such as severe patients
- How is case surveillance being conducted, are they actively looking for new cases
- How are they testing the accuracy of diagnostic tests

Thanks,

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, February 21, 2020 11:05 PM

To:

The final 3 pages are withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and are not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: RE: RaTG13

Date: 2020/05/27 18:58:13

Priority: Normal

Type: Note

~~Classification: TOP SECRET~~ (b)(3):10 USC 424; (b)(6)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Declassify on:~~ 20451021

=====

your three paragraphs below are a good summary based on the sources you have.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, May 27, 2020 12:23 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: RaTG13

Classification: TOP SECRET

Classified By:

Derived From:

Declassify On: 20451231

(b)(3):10 USC 424; (b)(3):50 USC
3024(i): (b)(6)

=====

Gentlemen,

I've been piecing together recent open and classified reports on SARS-CoV-2's closest known relative, setting aside for the moment the question of whether it actually exists (which I do not think is necessary to assume for the thoughts below). I've attempted to pull this together in the 3 paragraphs below, with references attached. I know this is very much in the weeds, and I surely haven't explained in the clearest possible way. If you can get through it, I would be grateful for any thoughts, as it's possible I do not have the details, chronology, or logic straight. Thank you!

V/r,

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

The final page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: RE: Request home telework Wed 13 May

Date: 2020/05/12 10:14:00

Priority: Normal

Type: Note

Classification: UNCLASSIFIED

Thank you

From:

Sent: Tuesday, May 12, 2020 9:46 AM (b)(3):10 USC 424; (b)(6)

To:

Cc:

Subject: RE: Request home telework Wed 13 May

Classification: UNCLASSIFIED

No problem in case he needs to frontload some assistance from you today for his briefings this week.

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

Sent: Tuesday, May 12, 2020 9:11 AM

To: (b)(3):10 USC 424
Subject: Request home telework Wed 13 May

Classification: UNCLASSIFIED
=====

If possible, I would like to telework tomorrow, Wed 13 May, for home-front coverage. Much of my current work is reading open-source scientific publications (SARS-CoV-2 and other CoVs), so I can continue to make progress.

Thank you,

(b)(3):10 USC 424;
(b)(6)

=====
Classification: UNCLASSIFIED

=====
Classification: UNCLASSIFIED

=====
Classification: UNCLASSIFIED

	(b)(3):10 USC 424; (b)(6)
Sender:	
Recipient:	
Sent Date:	2020/05/12 10:14:59
Delivered Date:	2020/05/12 10:14:00

(b)(3):10 USC 424; (b)(6)

From: [REDACTED]

To: [REDACTED]

Subject: RE: request on (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

Date: 2020/05/05 08:08:00

Priority: Normal

Type: Note

~~Classification: TOP SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

(b)(3):10 USC 424;
(b)(6) we are tracking this and your comments are spot on! I have some papers for you on the low-side if you wish. Will send them this morning. (b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6) (b)(3):10 USC 424; (b)(6)

Sent: Monday, May 4, 2020 10:48 PM

To: [REDACTED]

Cc: [REDACTED]

Subject: request on (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classification: TOP SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

[REDACTED]

The final page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

This is page 2. The first page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

(b)(3):50 USC 3024(i)

I would like to discuss this further if you have time today.

Thanks,

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

Sent: Thursday, May 14, 2020 4:48 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE:

~~Classification: TOP SECRET~~

(b)(3):50 USC 3024(i)

(b)(1); (b)(3):50 USC
3024(i); Sec. 1.4(c);
Sec. 1.4(e)

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~

(b)(3):50 USC 3024(i)

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

Can you redirect it?

Thanks,

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, May 14, 2020 7:34 AM

To:

(b)(3):10 USC 424; (b)(6)

Cc: [redacted] (b)(3):10 USC 424; (b)(6)

Subject: RE: [redacted]

~~Classification: TOP SECRET/~~ (b)(3):50 USC 3024(i)

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

Hi [redacted] (b)(3):10 USC 424; (b)(6)

(b)(3):50 USC 3024(i)

This is on hold right now. I reached out [redacted] on Monday to corroborate whether [redacted] in the [redacted] was correct and I haven't heard back.

Happy to talk more about it though. I'm continuing to do a bit more research in hopes of corroborating the information.

[redacted] (b)(3):10 USC 424; (b)(6)

From: [redacted] (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, May 13, 2020 3:13 PM

To: [redacted]

Cc: [redacted] (b)(3):10 USC 424; (b)(6)

Subject: RE: [redacted]

~~Classification: TOP SECRET/~~ (b)(3):50 USC 3024(i)

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~ (b)(3):50 USC 3024(i)

=====

[redacted] (b)(3):10 USC 424; (b)(6)

Another reason I want to start using the tracker, I gave it a quick look on Monday, but have not gotten back to [redacted] yet, it got pushed to the back of my radar.

So no we haven't.

[redacted] (b)(3):10 USC 424; (b)(6)

From: [redacted] (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, May 13, 2020 3:08 PM

To: [redacted] (b)(3):10 USC 424; (b)(6)

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

~~Classification: TOP SECRET~~

(b)(3):50 USC
3024(i)

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~

(b)(3):50 USC 3024(i)

=====

Have you all discussed this yet?

From:

(b)(3):10 USC 424; (b)(6)

Sent: Monday, May 11, 2020 2:44 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject:

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

~~Classification: TOP SECRET~~

(b)(3):50 USC 3024(i)

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On:~~

(b)(3):50 USC 3024(i)

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)

From: [REDACTED]

To: [REDACTED]

Subject: RE [REDACTED]

Date: 2020/04/20 10:30:00 (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

Priority: Normal

Type: Note

~~CLASSIFICATION: TOP SECRET~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, April 20, 2020 8:49 AM

To: (b)(3):10 USC 424; (b)(6) (b)(1); (b)(3):10 USC 424; Sec. 1.4(c); Sec. 1.4(e)

Subject: RE [REDACTED]

~~CLASSIFICATION: TOP SECRET~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC 424; (b)(6)

I have not! Thank you for sending. I will take a look.

Best,

(b)(3):10 USC
424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Monday, April 20, 2020 8:46 AM

To: (b)(3):10 USC 424; (b)(6)

Subject: FW: [REDACTED]

(b)(1); (b)(3):50 USC
3024(i); Sec. 1.4(c);
Sec. 1.4(e)

~~Classification: TOP SECRET/~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(3):10 USC
424; (b)(6)

have you seen this? If so, I would be interested in your thoughts.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424

Sent: Monday, April 20, 2020 7:07 AM

To: (b)(3):10 USC 424

Subject: [REDACTED]

(b)(1); Sec. 1.4(c);
Sec. 1.4(e)

~~Classification: TOP SECRET/~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From: Multiple Sources~~

~~Declassify On: 20451231~~

=====

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e); (b)(6)

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

	(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)
From:	
To:	
Subject:	RE: SARS-CoV-2 origin [redacted] updates slides
Date:	2020/06/19 12:51:43
Priority:	Normal (b)(3):10 USC 424; (b)(3):50 USC 3024(i)
Type:	Note

~~Classification: SECRET//NOFORN~~

~~Classified By:~~ (b)(3):10 USC 424; (b)(6)
~~Derived From:~~
~~Declassify On: 20450421~~

=====

(b)(3):10 USC 424; (b)(6)

I attempted to send a meeting update with the [redacted] and updated slides, but am sending again here just to be sure. Updated slides are attached; [redacted] (b)(3):10 USC 424 (both same as in meeting update just sent). Thank you for joining us!

(b)(3):10 USC 424;
(b)(6)

-----Original Appointment-----

From: (b)(3):10 USC 424; (b)(6)

Sent: Thursday, June 18, 2020 12:29 PM

To: [redacted] (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

(b)(3):10 USC 424; (b)(6)

(b)(3):50 USC 3024(i)

Subject: SARS-CoV-2 origin [redacted]

When: Friday, June 19, 2020 1:00 PM-2:00 PM (UTC-05:00) Eastern Time (US & Canada).

Where: [redacted] & updated slides

~~Classification: SECRET//NOFORN~~

(b)(3):10 USC 424

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

UPDAGE 19 JUN: Updated slides are attached

UPDATE 18 JUN: Updated slides are attached.

Dear colleagues,

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

We are grateful for your expertise as we continue this line of analysis!

V/r,

(b)(3):10 USC 424; (b)(6)

=====

~~Classification: SECRET//NOFORN~~

=====

~~Classification: SECRET//NOFORN~~

The final page is withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6) and is not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: RE: SARS-CoV-2 related virus information

Date: 2020/05/29 14:45:16

Priority: Normal

Type: Note

(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On:~~ 20451231

=====

(b)(3):10 USC 424; (b)(6)

Thanks [] It was a very interesting discussion!

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From:

Sent: Friday, May 29, 2020 1:14 PM

To:

Subject: SARS-CoV-2 related virus information

(b)(3):50 USC 3024(i)

~~Classified By:~~ (b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

~~Derived From:~~

~~Declassify On:~~ 20451231

=====

(b)(3):10 USC 424; (b)(6)

The final page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6) and is not provided.

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

(b)(3):10 USC 424; (b)(6)

(b)(3):50 USC 3024(i)

Yes, sounds like they're up on [redacted] email, just not phone.

(b)(3):10 USC 424; (b)(6)

From:

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

Sent: Thursday, April 23, 2020 12:48 PM

To:

Subject: RE:

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

~~Classification: SECRET//NOFORN~~

~~Classified By:~~

(b)(3):10 USC 424; (b)(6)

~~Derived From:~~

~~Declassify On: 20450421~~

=====

(b)(3):10 USC 424; (b)(6)

(b)(3):50 USC 3024(i)

I thought their [redacted] were down for a couple weeks? Are they OK now? If so, that would be the most prudent way to start.

(b)(3):10 USC 424; (b)(6)

(b)(3):50
USC 3024(i)

(b)(3):10 USC 424; (b)(6)

From:

To:

Subject: RE: [redacted] report

Date: 2020/05/15 14:25:00

Priority: Normal

Type: Note

~~Classified By: (b)(3):10 USC 424; (b)(6)~~

~~Derived From: (b)(3):10 USC 424; (b)(6)~~

~~Declassify On: 20450421~~

Thank you, [redacted] Hope you have a good weekend.

Best,

(b)(3):10 USC 424; (b)(6)

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, May 15, 2020 2:10 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: RE: [redacted] report

~~Classified By: (b)(3):10 USC 424; (b)(6)~~

(b)(3):50 USC 3024(i)

~~Derived From: (b)(3):10 USC 424; (b)(6)~~

~~Declassify On: 20450421~~

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Friday, May 15, 2020 12:10 PM

To: (b)(3):10 USC 424; (b)(6)

Subject: (b)(3):50
USC
3024(i) report

The final page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and (b)(6), and is not provided.

(b)(3):10 USC 424; (b)(6)

From:

To:

CC:

Subject: RE: WHO: New name for new coronavirus COVID-19

Date: 2020/02/12 09:43:11

Priority: Normal

Type: Note

~~Classification~~ UNCLASSIFIED

=====

(b)(3):10 USC 424; (b)(3):50 USC 3024(i); (b)(6)

(b)(3):10 USC 424

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, February 12, 2020 9:24 AM

To:

(b)(3):10 USC 424;
(b)(6)

Cc:

Subject: RE: WHO: New name for new coronavirus COVID-19

~~Classification:~~ UNCLASSIFIED

I'm editing a paper now that has gone thru second level review. Can we please get some guidance on virus and disease nomenclature?

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, February 12, 2020 9:21 AM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: WHO: New name for new coronavirus COVID-19

~~Classification:~~ UNCLASSIFIED

I'm reading that yesterday the International Committee on Taxonomy of Viruses came up with "SARS-CoV-2" as the new name of the virus. So, COVID-19=disease, SARS-CoV-2=virus. Glad that's all clear!

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, February 12, 2020 8:59 AM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: WHO: New name for new coronavirus COVID-19

~~CONFIDENTIAL~~ UNCLASSIFIED

=====

It is not entirely clear but it seems WHO is calling the disease COVID-2019 but the virus remains 2019-nCoV. If that is the case, when or if we adapt the COVID-2019 name we'll need to be careful to use the two names appropriately.

V/R

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, February 12, 2020 8:18 AM

To:

Cc:

(b)(3):10 USC 424;
(b)(6)

(b)(3):10 USC 424; (b)(6)

Subject: RE: WHO: New name for new coronavirus COVID-19

~~CONFIDENTIAL~~ UNCLASSIFIED

I would think so. The name issue has been talked about for weeks and WHO is the organization to do it.

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Wednesday, February 12, 2020 8:09 AM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: RE: WHO: New name for new coronavirus COVID-19

~~CONFIDENTIAL~~ UNCLASSIFIED

So we should definitely update everything in the production pipeline to reflect the name change, no?

(b)(3):10 USC 424; (b)(6)

From: (b)(3):10 USC 424; (b)(6)

Sent: Tuesday, February 11, 2020 2:11 PM

To:

Cc:

(b)(3):10 USC 424; (b)(6)

Subject: WHO: New name for new coronavirus COVID-19

~~Classification:~~ UNCLASSIFIED
=====

Today, WHO has declared a new name for the recently emerged coronavirus keeping us busy. Its:

COVID-19

(b)(3):10 USC 424; (b)(6)

=====
~~Classification:~~ UNCLASSIFIED

=====
~~Classification:~~ UNCLASSIFIED

=====
~~Classification:~~ UNCLASSIFIED

=====
~~Classification:~~ UNCLASSIFIED

=====
~~Classification:~~ UNCLASSIFIED

The final page is withheld in full citing (b)(3) 10 USC 424 and (b)(6) and is not provided.



DEFENSE INTELLIGENCE AGENCY

DIA_C_01570_A

April 21, 2020

(U) Worldwide: Progress of COVID-19 Vaccine Development

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

[Redacted content]

Committed to Excellence in Defense of the Nation

(U) Status of COVID-19 Vaccine Development

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(U) This graphic represents the most-advanced COVID-19 vaccine development as of 17 April 2020. The two most promising vaccine approaches are an mRNA-based vaccine, which instructs the patient's immune system to produce proteins that could prevent disease, and an adenovirus-based vaccine, which inserts a relevant COVID-19 gene into another innocuous virus to produce a robust antibody response.³⁴

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

The following page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and is not provided.

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

³⁴ (U) Book, Shakti Singh et al | 11 Nov 2018 | 11 Nov 2018 | (U) Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects | <https://www.reseachgate.net/publication/328875899>, 01 Apr 2020

(b)(3):10 USC 424

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i);
(b)(6)

> (U) Coronavirus engineering capabilities have matured worldwide over 20 years,
according to a review¹⁴

(b)(1); (b)(3):10 USC 424;
(b)(3):50 USC 3024(i); Sec.
1.4(c); Sec. 1.4(e); (b)(6)

The following page is withheld in full citing (b)(1) and (b)(3) 50 USC 3024(i) and is not
provided.

(b)(3):50 USC 3024(i)

¹⁴ (U) Almazan F, Gonzalez JM, Penzes Z; Virus Res; 12 June 2014; (U) Coronavirus reverse genetic systems: Infectious clones and replicons; Overall classification is U.

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

(U) Summary

(U//~~FOUO~~) (b)(3):10 USC 424 As of early to mid-August 2020, open source reporting indicated that Russian and Chinese pharmaceutical companies would trial COVID-19 vaccines in countries including Saudi Arabia, the United Arab Emirates (UAE), and Bahrain. A Russian science and technology firm, Gamaleya Institute, would conduct clinical trials of a COVID-19 vaccine candidate named Sputnik-V in Saudi Arabia and UAE. Open source reporting also indicated that that Chinese pharmaceutical firms, Sinopharm and CanSino, would trial COVID-19 vaccines in Bahrain, UAE, and Saudi Arabia.



(U) Figure 1: Image of Russian COVID-19 vaccine candidate

(U) Potential Trials of a Russian COVID-19 Vaccine Candidate in UAE, and Saudi Arabia

(U) As of early to mid-August 2020, open source reporting indicated that a Russian science and technology firm, Gamaleya Institute, would conduct clinical trials of a COVID-19 vaccine candidate named Sputnik-V in Saudi Arabia and the United Arab Emirates (UAE). Russian President Vladimir Putin and Russian state-

(b)(3):10 USC 424; (b)(6)

sponsored press reporting claimed that Sputnik-V was in its third phase of clinical trials. The Sputnik-V vaccine was developed by the Russian Direct Investing Fund (RDIF) and the Gamaleya Institute (Figure 2). The vaccine was named after Russia's first satellite launched in 1957. As of mid-August 2020, Gamaleya and the RDIF had not published peer-reviewed results, and a World Health Organization database listed the Sputnik-V vaccine as being in Phase I of testing stage during the same time period.

(U) Sputnik-V was described as a “viral vector vaccine based on a human adenovirus — a common cold virus — fused with the spike protein of SARS CoV,” and was compared as being similar to vaccine candidates developed by Chinese companies. Russian news and general technical websites reported that Sputnik-V used “two different adenovirus vectors across two injections” in order to boost its effectiveness. According to Russia's Health Minister Mikhail Murashko, volunteers did not develop “serious complications” from the immunization and developed “high” levels of COVID-19 antibodies.

(U) According to statements by RDIF's Chief, Kirill Dmitriev, RDIF would be able to produce “more than 500 million doses a year in five countries.” Kirill Dmitriev stated RDIF would mass-produce the vaccine in India, South Korea, Brazil, Saudi Arabia, Turkey and Cuba. Industrial production would reportedly begin in September 2020. Phase III trials began on 12 August 2020. Phase III would reportedly require thousands of human trials. Kirill Dmitriev stated that RDIF would conduct Phase III clinical trials in countries including Saudi Arabia, the United Arab Emirates, Brazil, India, and the Philippines.

(U) As early as 17 July 2020, social media users commented on the possibility of clinical trials being held in Saudi Arabia for a vaccine candidate developed by the Gamaleya Institute.

(U) In early August 2020, Philippine president Rodrigo Duterte confirmed that the Sputnik-V vaccine would potentially be trialed in the Philippines stating, “when the vaccine arrives...I will get injected.”

(U) Russian websites indicated that a pharmaceutical company, Binnopharm, located in Zelenograd, Russia, would produce the vaccine candidate Sputnik-V. According to Binnopharm's website, the vaccine's first dose develops “humoral cellular immunity” while a second dose forms “memory cells”. The Sputnik-V registration certificate published on an official Russian website listed the components and stages of its production (Figure 3, next page).



(U) Figure 2: Images of Sputnik-V released by RDIF

UNCLASSIFIED		П-006398	Дата регистрации: 11.08.2020	Дата окончания действия: 01.01.2021		
Срок лицензия гражданского оборота: 5 лет						
1	Наименование держателя или владельца регистрационного удостоверения лекарственного препарата	ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России (Филиал "Медгарм")				
2	Страна	Россия				
3	Торговое наименование лекарственного препарата	Гам-КОВИД-Вак: Квибиотерапевтические векторы на основе для профилактики коронавирусной инфекции, выз				
4	Международное непатентованное или группировочное или химическое наименование	Вакцина для профилактики новой коронавирусной инфекции (COVID-19)				
5	Формы выпуска	Лекарственная форма	Дозировка	Срок годности		
		раствор для внутримышечного введения	компонент I-0.5 мл/доза; компонент II-0.5 мл/доза	6 мес		
		Условия хранения				
		В защищенном от света месте, при температуре не выше минус 18 град. (не допускается хранение размороженного препарата)				
		0.5 мл (1 доза) - ампулы (5 шт.) - пачки картонные /компонент I/- Применение препарата возможно только в условиях медицинских организаций, имеющих право осуществлять вакцинопрофилактику населения в установленном законодательством порядке. Проведение пострегистрационных клинических исследований, результаты которых являются основанием для оценки отношения ожидаемой пользы к возможному риску применения лекарственного препарата при подтверждении его государственной регистрации. Лекарственный препарат для медицинского применения подлежит обязательному послеприему выборочному контролю качества лекарственных средств в соответствии с законодательством Российской Федерации. Уведомление Федеральной службы по надзору в сфере здравоохранения и обеспечение учета каждого факта применения лекарственного препарата в Единой государственной информационной системе в сфере здравоохранения. 0.5 мл (1 доза) - ампулы (5 шт.) - пачки картонные /компонент II/- Применение препарата возможно только в условиях медицинских организаций, имеющих право осуществлять вакцинопрофилактику населения в установленном законодательством порядке. Проведение пострегистрационных клинических исследований, результаты которых являются основанием для оценки отношения ожидаемой пользы к возможному риску применения лекарственного препарата при подтверждении его государственной регистрации. Лекарственный препарат для медицинского применения подлежит обязательному послеприему выборочному контролю качества лекарственных средств в соответствии с законодательством Российской Федерации. Уведомление Федеральной службы по надзору в сфере здравоохранения и обеспечение учета каждого факта применения лекарственного препарата в Единой государственной информационной системе в сфере здравоохранения. 0.5 мл (1 доза) - флаконы - пачки картонные /компонент I/- Применение препарата возможно только в условиях медицинских организаций, имеющих право осуществлять вакцинопрофилактику населения в установленном законодательством порядке. Проведение пострегистрационных клинических исследований, результаты которых являются основанием для оценки отношения ожидаемой пользы к возможному риску применения лекарственного препарата при подтверждении его государственной регистрации. Лекарственный препарат для медицинского применения подлежит обязательному послеприему выборочному контролю качества лекарственных средств в соответствии с законодательством Российской Федерации. Уведомление Федеральной службы по надзору в сфере здравоохранения и обеспечение учета каждого факта применения лекарственного препарата в Единой государственной информационной системе в сфере здравоохранения. 0.5 мл (1 доза) - флаконы - пачки картонные /компонент II/- Применение препарата возможно только в условиях медицинских организаций, имеющих право осуществлять вакцинопрофилактику населения в установленном законодательством порядке. Проведение пострегистрационных клинических исследований, результаты которых являются основанием для оценки отношения ожидаемой пользы к возможному риску применения лекарственного препарата при подтверждении его государственной регистрации. Лекарственный препарат для медицинского применения подлежит обязательному послеприему выборочному контролю качества лекарственных средств в соответствии с законодательством Российской Федерации. Уведомление Федеральной службы по надзору в сфере здравоохранения и обеспечение учета каждого факта применения лекарственного препарата в Единой государственной информационной системе в сфере здравоохранения.				
6	Сведения о стадиях производства	№ п/п	Стадия производства	Промышленность	Адрес производства	Страна
		1	Выпускающий контроль качества	ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России (Филиал "Медгарм") ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России	123098, г. Москва, ул. Гамалеи, д.18	Россия
		2	Производитель (готовая ЛР)	Акционерное общество "Биннофарм" (АО "Биннофарм")	124460, г. Москва, г. Зеленоград, ул. Конструктора Гусикова, д. 3, стр. 1	Россия
		3	Производитель (готовая ЛР)	ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России (Филиал "Медгарм") ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России	123098, г. Москва, ул. Гамалеи, д.18	Россия
		4	Упаковщик (ассоциированная первичная упаковка)	Акционерное общество "Биннофарм" (АО "Биннофарм")	124460, г. Москва, г. Зеленоград, ул. Конструктора Гусикова, д. 3, стр. 1	Россия
		5	Упаковщик (ассоциированная первичная упаковка)	ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России (Филиал "Медгарм") ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России	123098, г. Москва, ул. Гамалеи, д.18	Россия
		6	Упаковщик (ассоциированная вторичная/третичная упаковка)	Акционерное общество "Биннофарм" (АО "Биннофарм")	124460, г. Москва, г. Зеленоград, ул. Конструктора Гусикова, д. 3, стр. 1	Россия
		7	Упаковщик (ассоциированная вторичная/третичная упаковка)	ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России (Филиал "Медгарм") ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России	123098, г. Москва, ул. Гамалеи, д.18	Россия
7	Инструкция по применению лекарственного препарата	Показать инструкцию				
8	Нормативная документация	№ п/п	Наименование	Год	№ п/п	Наименование
		1	ИП-006398-110820	2020		
9	Фармакотерапевтическая группа	ММДП - вакцина				
10	Анатомо-терапевтическо-химическая классификация	J07B ВАКЦИНЫ ДЛЯ ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ				
11	Фармацевтическая субстанция	Наличие лекарственного препарата в перечне ЖНВЛП				
12	Особые отметки	Наличие в лекарственном препарате наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации в соответствии с законодательством Российской Федерации, международными договорами Российской Федерации, в том числе Единой конвенцией о наркотических средствах 1953 года и Конвенцией о психотропных веществах 1971 года				

(U) Figure 3: Registration Certificate in original Russian


(U) Potential Trials of a Chinese Vaccine Candidate in UAE, Bahrain, and Saudi Arabia

(U) Chinese firms have also initiated or announced plans for clinical trials in both Saudi Arabia and the UAE. Chinese-based pharmaceutical company, Sinopharm, initiated Phase III clinic trials in Abu Dhabi, UAE. Sinopharm is partnering with Sinopharm's China National Biotech Group (CNBG), the Abu Dhabi government, and the Abu Dhabi-based artificial intelligence company, G42 Healthcare.

(U) According to the website Clinical Trials Arena, health practitioners from Abu Dhabi Health Services (SEHA) would manage the Sinopharm trial, and would include a mobile clinic to aid accessibility. Sinopharm reportedly selected the UAE for its 200+ nationalities, according to G42 Healthcare. The UAE authorized up to 15,000 volunteers for the trials. G42 and SEHA intend to enroll at least 5,000 participants between 18-60 years old for the first stage of human trials. On 2 August 2020, a Tweet from an official account of the Abu Dhabi Government Media Office advertised a field clinic at the Abu Dhabi National Exhibition Centre (ADNEC) to register, examine, and select volunteers (Figure 4).

(U) As of 25 July 2020, an official Twitter account for ADNEC stated that the convention center had welcomed more than 10,000 volunteers for the vaccine trial (Figure 5).

(U) As of 6 August 2020, more than 5,000 volunteers were reportedly administered the first of two doses. Both doses are to be administered within 28 days according to open sources. At least 15,000 volunteers were required to complete the first stage of human trials. In addition to the general public, the Abu Dhabi



(U) Figure 4: Tweet from official UAE account



(U) Figure 5: Tweet from official ADNEC account

Department of Health Chairman Al Hamed and acting Undersecretary Alkaabi would also participate in the Sinopharm trials. In a press release from 16 July 2020, G42 stated the UAE Health Chairman Al Hamed was "the first to participate" in the UAE trials.

(U//~~FOUO~~) (b)(3):10 USC 424 In a press release praising the ADNEC partnership with SHEA to combat COVID-19, Humaid Matar Al Dhaheri, Managing Director & Group CEO, revealed that "Prime Assessment Centers" were established in the ICC Hall of the ADNEC (b)(3):10 USC 424

(Figure 6).

(U) G42 Healthcare would also conduct trials in Bahrain, according to Bahrain's Assistant Secretary for Public Health Al Hajri. Al Hajri stated they would test approximately 6,000 volunteers over 12 months. Volunteers made up of Bahrain citizens and residents are required to be over 18 years of age without any chronic or underlying medical conditions to participate.



(U) Figure 6: ADNEC Press Statement on partnership with SHEA

(U) Technology blogs and sites describe G42 as a "leading" artificial intelligence (AI) and cloud computing company based in the UAE. According to technology investment sites, G42 is part of the Gulf Cooperation Council, has one acquisition and three investments, and has between 251-500 employees. Its CEO is Peng Xiao.

(U) In late May 2020, G42's health-focused division, "G42 Healthcare," rolled out an AI evaluation platform to help identify the virus genome. According to Emirati news sites, the "platform uses deep neural networks to segment the abnormalities observed in the CT scan, such as Ground Glass Opacities, and consolidations to enable rapid quantification of their extent on patient's CT scan." The article further stated that G42 launched a "groundbreaking detection laboratory" in Masdar City, Abu Dhabi.

(U) Separately, another Chinese firm, CanSino, would reportedly launch Phase III trials of its COVID-19 vaccine candidate "Ad5-nCOV" in Saudi Arabia. Created in collaboration with China's military research unit, it is composed of the adenovirus type-5 cold virus "to deliver genetic material from the coronavirus into the body."

(U) The Saudi Ministry of Health stated CanSino trials would take approximately 5,000 participants and would be conducted over multiple cities including Riyadh, Dammam, and Mecca. According to the Saudi Health Ministry, one group of participants would receive low dosages of the Ad5-nCOV vaccine while others would

receive a placebo. Research teams will reportedly follow up with participants to ensure no side effects appear. Research teams would conduct follow-ups by unspecified electronically facilitated means.

(U) CanSino conducted the first two trials in China. Phase I included 108 volunteers from 16-27 March 2020. Phase II included 603 volunteers with two doses from 11-16 April 2020. The website Clinical Trials Arena reported that Ad5-nCOV results showed a "favourable efficiency profile," and that COVID-19 antibodies showed up in participants' plasma with few side effects.

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

The final 2 pages are withheld in full citing (b)(3) 10 USC 424 + 50 USC 3024(i) and are not provided.

(b)(3):50 USC 3024(i)

~~TOP SECRET~~

~~(S//NF)~~ (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

~~(S//NF)~~ (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]ⁱ
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]ⁱⁱ
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]ⁱⁱⁱ

~~(S//NF)~~ (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{iv}
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^v
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{vi}

~~(S//NF)~~ (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{vii}
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{viii}
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{ix}

~~(S//NF)~~ (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^x
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{xi}
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{xii}

~~(S)~~ (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{xiii}

(b)(3):50 USC 3024(i)

~~TOP SECRET~~

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); (b)(6)

~~TOP SECRET~~

(b)(3):50 USC 3024(i)

- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{xiv}
- (CLASSIFICATION) According to SOURCE, [insert evidence]. [Explanation/reasoning/linking logic as needed]^{xv}

ⁱ Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

ⁱⁱ Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

ⁱⁱⁱ Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{iv} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^v Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{vi} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{vii} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{viii} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{ix} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^x Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{xi} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{xii} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{xiii} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{xiv} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

^{xv} Source – If it is journal article, at a minimum please include lead author, year published, and title of paper

~~TOP SECRET~~

(b)(3):50 USC 3024(i)